Capricor Q1 net loss $33.9M ($0.59/share); Deramiocel BLA PDUFA Aug 22, 2026

CAPRICOR THERAPEUTICS, INC.

• Net loss of $33.9M ($0.59/share) for Q1 2026 vs net loss of $24.4M ($0.53/share) in Q1 2025.
• Cash balance of $278.6M as of March 31, 2026; expected to support operations through Q4 2027.
• Deramiocel BLA under active FDA review; PDUFA target action date of August 22, 2026; labeling discussions expected soon.
• Filed suit against Nippon Shinyaku/NS Pharma citing flawed pricing in distribution agreement; seeking rescission and preliminary injunction.
• New Chief Commercial Officer with direct DMD experience expected to join in coming weeks; eligible for Priority Review Voucher upon approval.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.